95 results about "Ischemia" patented technology

The invention discloses an electrocardio data processing and coronary heart disease risk prediction method, device and system and a medium. The method comprises the steps of obtaining exercise electrocardio data output through at least one electrocardiogram lead; analyzing the exercise electrocardiogram data to obtain a heart rate sequence corresponding to each electrocardiogram lead; extracting a QRS wave group corresponding to each heart beat from the exercise electrocardio data; dividing a plurality of heart rate intervals according to the obtained heart rate sequence; according to the heart rate interval to which the heart rate corresponding to each QRS wave group belongs, classifying the QRS wave group into a group corresponding to the corresponding heart rate interval; determining an average QRS wave group corresponding to each heart rate interval according to all the QRS wave groups in each group; extracting the high-frequency energy of the average QRS wave group corresponding to each heart rate interval; and determining an energy sequence according to the high-frequency energy corresponding to each heart rate interval. According to the scheme, high-frequency components and dynamic load information which are more sensitive to ischemia are utilized, so that the detection rate and the identification capability of coronary heart diseases, particularly early and mild lesions, can be remarkably improved.

The utility model relates to medical instrument technical field especially is a kind of wearable femoral vein compression hemostasis device, including disposable underpants body, the upper surface of one side of trouser leg is located at femoral vein and is fixedly installed with the compression assembly for fixing wound, and the compression assembly includes clamping ring plate, the middle part of clamping ring plate is equipped with four groups of insertion slot, the surface both sides of waistband are fixedly installed with trouser loop, and the periphery of waistband is provided with the bandage assembly for exerting pressure and is set, and the bandage assembly includes waist bandage and leg bandage, the both ends of waist bandage are insertedly installed in the inside of insertion slot, the both ends of leg bandage are also insertedly installed in the inside of insertion slot, the both ends of waist bandage can be folded and detachably connected, and the both ends of leg bandage can be folded and detachably connected.The utility model is folded and detachably connected by underpants design, bandage, clamping ring plate disperses pressure, reduces the risk of local ischemia, and waist bandage and leg bandage synergistic effect, form three-dimensional compression.

A method, device, system and medium for electrocardio data processing and coronary heart disease risk prediction, motion electrocardio data output through at least one electrocardio lead is acquired; the motion electrocardio data is analyzed to obtain a heart rate sequence corresponding to each electrocardio lead; each QRS complex corresponding to each heartbeat is extracted from the motion electrocardio data; a plurality of heart rate intervals are divided according to the obtained heart rate sequence; each QRS complex is classified into a group corresponding to a heart rate interval according to the heart rate interval to which the heart rate corresponding to the QRS complex belongs; the average QRS complex corresponding to each heart rate interval is determined according to all QRS complexes in each group; the high-frequency energy of the average QRS complex corresponding to each heart rate interval is extracted; and an energy sequence is determined according to the high-frequency energy corresponding to each heart rate interval. The present scheme uses high-frequency components and dynamic load information which are more sensitive to ischemia, and can significantly improve the detection rate and discrimination ability for coronary heart disease, especially early and mild lesions.

The invention discloses a pressure monitoring device and method for evaluating pressure sore risk, and relates to the technical field of medical equipment. The system comprises a pressure sensing unit used for collecting pressure distribution data between the body surface of a patient and a supporting surface; the distance measuring device is used for measuring the distance between the device and the body surface of the patient. According to the method, information of three different dimensions of pressure distribution, body surface image and deep thermal imaging is subjected to fusion analysis, a pressure sensor positions a high-risk pressed area, a high-definition color image is used for identifying macroscopic skin damage and color change, infrared thermal imaging can penetrate through a surface layer, and the image can be used for identifying the skin damage and color change. According to the method, deep tissue temperature abnormity caused by ischemia and inflammation is sensitively captured, and the three types of information are integrated into a quantitative comprehensive risk score through a weighting algorithm, so that an evaluation result does not depend on subjective experience of nursing personnel any more and is converted into objective and quantifiable accurate diagnosis, and the screening accuracy of high-risk patients is remarkably improved.

The invention belongs to the technical field of medicines, and particularly relates to application of penicillin tenuipes in preparation of a product for preventing or treating ischemic encephalopathy, cell experiments and animal experiments show that penicillin tenuipes has a good treatment effect on cerebral thrombosis and middle artery embolism, can obviously improve behavioral scores after ischemia, and can be used for preparing a medicine for preventing or treating ischemic encephalopathy. And cerebral thrombus and blood vessel diameter conditions. The penicillin tenuipes also has an anti-inflammatory effect. Therefore, the compound can be used for preparing medicines for preventing or treating ischemic encephalopathy.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

Liposomal trans-crocetin pharmaceutical compositions, dosing regimens and methods of treating or preventing disorders and conditions associated with, but not limited to, infection, ischemia, hypoxia, ARDS, inflammation, sepsis, shock, stroke, traumatic injury, and proliferative disorders such as cancer are provided. Methods of using the provided trans-crocetin pharmaceutical compositions and dosing regimens to treat cardiovascular, renal, liver, inflammatory, metabolic, pulmonary, neurological, and other disorders and conditions are also provided, as are methods of increasing the delivery of oxygen and increasing the efficacy of a therapeutic agent using the provided compositions and dosing regimens.

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

The invention discloses application of a BTK inhibitor in preparation of a medicine for treating acute kidney injury and complications thereof. The invention provides a new strategy for treating acute kidney injury and complications thereof by using a BTK inhibitor, and particularly relates to application of the BTK inhibitor as an acute kidney injury medicine. The invention finds that serum creatinine and urea nitrogen levels can be effectively reduced by knocking out mouse BTK, and kidney injury is relieved and conversion from AKI to CKD is delayed or prevented by recovering kidney pathological structure and reducing apoptotic cell generation, which indicates that BTK is an effective target for treating acute kidney injury. Meanwhile, through treatment of an acute renal ischemia-reperfusion model, it is found that the BTK inhibitor such as ibrutinib can relieve ischemia-reperfusion induced renal function impairment and improve the renal function of a mouse, and it is indicated that the BTK inhibitor can serve as a treatment scheme for acute renal injury.

The invention belongs to the technical field of experimental animal models, biomedical research and immunology, and discloses a photocoagulation thymus ischemia animal model, a method and application of the photocoagulation thymus ischemia animal model in rapid simulation of thymus degeneration and immune senescence, and the model shows at least one or more characteristics 1-7 days after induction: thymus atrophy, thymus weight or thymus index is significantly reduced; the cortical-medullary structure of thymus is disordered or disappears; the expression distribution of the Keratin 5 / Keratin 8 is abnormal; thymic cell apoptosis is increased, and lipid deposition is enhanced; the proportion of CD4 + CD8 + double positive T cells is reduced, and the proportion of DN2 / DN3 stage T cells is increased; the initial T cell output is reduced; and the immune function is reduced. The pathological mechanism is clear; the modeling period is short, and the immune senescence phenotype can be stably obtained within several days; the injury focus is controllable, and systemic stress or hormone interference is avoided; the model has high repeatability and is suitable for mechanism research and drug screening.

Novel compositions of N-desmethyl ruboxistaurin L-lactate salt and L-lactate salt polymorphs. The use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs administered in combination with lithium or other treatments for bipolar disorder are also disclosed.

Provided herein are novel reprogrammed smooth muscle cells (rSMCs) and methods of making and using the cells for the treatment of ischemia. The rSMCs are produced by culturing a fibroblast with an all-trans-retinoic acid (ATRA) under conditions that produce the rSMC from the fibroblast, wherein the fibroblasts are genetically modified to overexpress myocardin. The rSMCs offer advantages over currently available regenerative vascular therapies by promoting vascular perfusion in a recipient subject. In particular, the rSMCs can increase neovascularization of both small and large vessels.

The utility model relates to the technical field of electrocardiogram lead wires, in particular to an electrocardiogram lead wire capable of reducing skin damage, which comprises a connector, and the front end and the rear end of the right side of the connector are respectively provided with a limb lead electrode wire and a chest electrode wire. Button type gel electrodes are arranged at the ends, away from the connector, of the limb lead electrode wires and the chest electrode wires, arc-shaped seats are fixedly connected to the outer sides of the limb lead electrode wires, and connecting seats are fixedly connected to the tops of the button type gel electrodes. Under the action of the button type gel electrode, the arc-shaped seat and the elastic capsule, the electrocardiogram lead wire has the advantage of reducing skin damage, and solves the problems that clips are clamped on four limbs, and clips are clamped at the tail ends of the limbs for a long time, so that local skin is easily damaged, even local tissues are ischemic, and the like. And therefore, some patients cannot insist at the end of the examination, the physical fitness of the patients is poor, and the technology is not easy to carry out.

The invention discloses a postoperative abdominal organ ischemia risk assessment method and system based on image analysis, and relates to the technical field of image analysis. The method comprises the following steps: acquiring an abdomen enhanced CT image of a target patient, and outputting the abdomen enhanced CT image after standardization processing; an improved 3D U-Net + + architecture of multi-task collaborative learning is adopted to perform joint segmentation on organs of a target patient and a target area, and geometric prior and a topological reasoning mechanism are fused; the method is technically characterized in that multi-task segmentation is adopted to enable RPPR calculation to focus on a real ischemic area, average dilution signals of all organs are avoided, and topological correction ensures that blood vessel features reflect real anatomy; in addition, through conjoint analysis of a hypoperfusion area prediction mask and a blood vessel VTIF, two ischemic subtypes of structural occlusion and functional hypoperfusion are disclosed, individualized development of a clinical intervention strategy is promoted, and the condition of required blood vessel intervention or conservative treatment is defined, so that the whole scheme has innovativeness and clinical landing value.

Described herein are novel methods for fractionating and isolating platelets, platelet- and extracellular vesicle-derived growth factors, exosomes, globulins, fibrinogen and albumin, and methods of using the isolated platelets, platelet and extracellular vesicle-derived growth factors, exosomes, globulins, fibrinogen and albumin for regenerating tissue in a subject, treating fibrinogenemia or a clotting deficiency in a subject, treating ischemia and hypoxia, treating dry-eye syndrome, an orthopedic disorder, or a dental disorder in a subject. Also described herein are growth media for culturing mammalian (e.g., human) cells.

The application discloses a drug balloon catheter which can keep the blood supply of the distal end, comprising a tip tube, a balloon, an inner tube and an outer tube, the proximal end of the balloon is fixed on the outer tube and the distal end of the balloon is fixed on the tip tube, the inner tube extends out of the outer tube and passes through the hollow cavity of the balloon, the distal end of the inner tube extends out of the balloon and communicates with the tip tube, and the drug balloon catheter further comprises a blood flow anti-blocking mechanism which is used for forming a blood flow passage which passes through the section where the balloon is located and communicates with the blood vessel in the drug balloon catheter. The application can keep the blood supply of the distal end through the blood flow passage without blocking the blood vessel during the interventional therapy, avoids the ischemia of the distal end, has a longer interventional therapy time, fully releases the drug, and is not easy to rebound and contract after the interventional therapy is completed.

This invention discloses a traditional Chinese medicine composition for improving diarrhea, belonging to the field of traditional Chinese medicine technology. Addressing the shortcomings of existing antidiarrheal techniques, which only treat the symptoms and not the root cause, have significant side effects, high recurrence rates, and easily cause damage to the intestinal microcirculation, this invention is based on the original microscopic pathogenesis of small intestinal microvascular spasm and ischemia, and abnormal intestinal fluid metabolism. It is prepared by combining peppermint, angelica dahurica, nutmeg, cinnamon, platycodon grandiflorus, and angelica sinensis. The synergistic effect of each herb can target and relax spasmodic small intestinal microvessels, restore normal intestinal blood perfusion, regulate intestinal peristalsis rhythm, bidirectionally regulate intestinal fluid secretion and reabsorption, and simultaneously block abnormal stress signals in the brain-gut axis, repairing intestinal microcirculatory damage. This invention has a scientifically formulated composition, mild medicinal properties, and no side effects. It addresses the root causes of various acute, chronic, and functional diarrheas caused by cold stimulation, emotional stress, and spleen deficiency with cold stagnation, exhibiting strong curative effect and an extremely low recurrence rate, possessing high clinical promotion and application value.

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

The invention relates to the technical field of biological medicine, in particular to an efficient macrophage targeting vesicle system as well as a preparation method and application thereof. The vesicle system is a chimeric vesicle (mHEs), and is prepared from extracellular vesicles (M2-EVs) derived from M2 type macrophages and apoptotic small bodies (MSC-ABs) derived from bone marrow mesenchymal stem cells. The vesicle system provided by the invention can realize specific recognition and functional regulation of macrophages, thereby playing an efficient therapeutic role in pathological processes such as tissue inflammation repair, myocardial infarction, ischemia-reperfusion injury and immune metabolism remodeling.

A system for managing liver disease, the system comprising an electronic medical record system comprising a plurality of patient records. The system comprising a patient management platform configured to access the electronic medical record (EMR) system to retrieve medical records of one or more patients, analyze the medical records to selectively identify data related to a liver condition, interface with one or more data analysis platforms configured to receive and analyze the data related to a liver condition. Based on analysis by the patient management interface and / or the data analysis platforms, a display is generated comprising: specific liver-related patient attributes and conditions, and at least one of: a liver health prognosis or a recommended treatment for addressing the liver condition corresponding to the one or more patients. The liver condition can comprise one or more of: cancer, cirrhosis, liver failure, fatty liver disease, steatosis, ischemia, and / or hepatitis.

This invention discloses a limb care device after cardiovascular interventional surgery, belonging to the field of medical auxiliary device technology. It includes a positioning unit, a compression unit, and a control unit. Through targeted structural design and collaborative control logic, it solves the contradiction between hemostasis and ischemia prevention in postoperative care, while improving nursing efficiency, stability, and safety. It uses the functional zoning of the central balloon in the puncture core area and the annular balloon in the surrounding auxiliary area, combined with the control logic that prioritizes the central balloon over the annular balloon, the annular balloon immediately stops circulation to maintain pressure when the pressure of the central balloon fluctuates. This ensures continuous hemostasis at the puncture site and avoids the risk of ischemia and thrombosis caused by long-term compression. The pressure threshold limitation, circulation reflux design, and emergency pause mechanism form multiple safety protections, reducing the risk of complications such as swelling and pain. It is also suitable for multiple puncture sites and patients of different body types, taking into account both medical and nursing efficiency and patient comfort.

This invention discloses a traditional Chinese medicine ionopolymer delivery agent, its preparation method, and its application in the prevention of diabetic foot ulcers, belonging to the field of pharmaceutical technology. The traditional Chinese medicine ionopolymer delivery agent comprises a vitamin B1 lipoic acid ionopolymer, safflower, kudzu root, and salvia miltiorrhiza, with a mass ratio of 4:(1-2):(2-4):(2-4). The delivery gel comprises the delivery agent, a gel matrix, and a preservative, with a mass ratio of 4:4:(0.45-0.7). This invention exhibits synergistic effects from multiple components, simultaneously improving local neuropathy, ischemia, hypoxia, and inflammatory responses in diabetic foot ulcers. It demonstrates good transdermal absorption, stable efficacy, and high safety. The preparation method is simple and easily industrialized, filling a gap in related effective topical preparations and possessing extremely high clinical application value.

This invention discloses a pressure-adjustable extravascular occlusion balloon with drainage and flushing function, relating to the field of vascular hemostasis technology. It includes a tubing wall with a C-shaped front end. Several balloons that can compress each other are arranged inside the C-shaped tube. A balloon catheter is inserted through the tubing wall, with one end connected to the balloon and the other end extending out from the rear end of the tubing wall. This invention can quickly control massive bleeding, achieving hemostasis without causing permanent loss of blood supply to the controlled blood vessel, thus avoiding related complications caused by ischemia.

The invention discloses a hemostatic stent for heart great vessel surgery, which belongs to the technical field of medical instruments and comprises a shell, an adjusting knob, a piston part, a limiting plate and an airtight plate. The piston piece can be driven to extrude gas by twisting the adjusting knob, so that the expansion ring on the shell quickly expands to extrude the inner wall of a blood vessel to realize hemostasis; a clamping row groove of a limiting plate is matched with a positioning edge block of the piston piece, reverse movement of the piston piece can be prevented, stable hemostasis is ensured, unlocking and resetting can be achieved by pressing a knob column, and repeated use is facilitated; when the expansion ring reaches the maximum expansion state, high pressure in the expansion cylinder pushes the elastic film to bend, so that the medicine blocking boss is separated from the medicine outlet hole, heparin in the end head is released, local blood coagulation is inhibited in a targeted mode, the medicine dosage is reduced, and the problems that blood vessel endothelium injury is easily caused, the ischemia risk is high, and continuous operation of an operator is needed due to hemostasis of existing artery forceps are solved.

The invention discloses application of curcumenone in preparation of a medicine for preventing and treating ischemia-reperfusion injury. The invention proposes and verifies that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury for the first time, and the compound can effectively protect hepatic tissues and avoid liver function damage by inhibiting the oxidative stress level of the hepatic tissues after ischemia reperfusion, avoiding cell ferroptosis and improving bone marrow-derived macrophages, so that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury. The invention provides a novel medicine with great application potential for preventing and treating ischemia reperfusion injury.

The disclosure is directed to novel solid-state forms of Compound 9 and pharmaceutically acceptable salts of Compound 9, compositions comprising the same, and methods of using the same, including use in treating cancer, hypoxia related pathologies, disorders leading to ischemia, and non-cancerous angiogenic diseases.

The application discloses application of growth differentiation factor 15 in preparation of products for diagnosis, prognosis and treatment of retinal arterial obstruction, and finds that serum GDF15 level of a patient with RAO is greater than or equal to 442.64 pg / mL, and is significantly positively correlated with the risk of RAO (OR=12.6), and the diagnostic accuracy can be improved by combining glucose, triglyceride and other indexes (AUC=0.922). The recombinant human GDF15 protein can inhibit ischemia and hypoxia RGC apoptosis and protect visual function. The application has important application value in early diagnosis of RAO, visual prognosis evaluation and targeted treatment.

The invention discloses an improved and simplified modeling method of a rat middle cerebral artery embolism ischemia model and an auxiliary precise thrombus pushing device.According to the modeling method, standardized thrombus embolism is prepared through an in-vitro step, and the modeling method comprises the steps that blood is incubated in a PE-50 catheter at the specific temperature for the specific time to form initial thrombus; the diameter is accurately controlled to be smaller than 0.14 mm through reciprocating push-pull and negative pressure folding suction of a PE-10 catheter; then, loading the emboli by using a normalized vascular catheter with a 20mm pre-mark; during modeling, the catheter is inserted to a preset depth through an external carotid artery, and the thrombus is pushed into a target blood vessel at a constant speed of 10-20 [mu] L / min by means of an auxiliary precise thrombus pushing device. The core problems of poor thrombus quality and low model stability and repeatability of a traditional method are effectively solved by optimizing the whole process of thrombus preparation, catheter specification, pushing rate and verification standard in combination with a special device, the success rate of the model can reach 90% or above, and an efficient and reliable experimental tool is provided for cerebral apoplexy research.

Methods for the detection, monitoring, and treatment of cardiac fibrosis, progression of cardiac fibrosis, or heart failure in a subject comprising: (a) contacting a sample obtained from the subject with a binding agent that binds a region of cartilage intermediate layer protein 1 (CILP) that spans the cleavage site of the CILP precursor or a nucleotide encoding same. The cardiac fibrosis may be associated with one or more of: ischemia, congenital defect, familial fibrosis, infiltrative fibrosis, idiopathic fibrosis, amyloidosis, hemosiderosis, valvular disease, and other idiopathic cardiomyopathies.